Bluechiip Ltd (ASX: BCT) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Bluechiip Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $15.74 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 787.09 million
Earnings per share -0.008
Dividend per share N/A
Year To Date Return -35.48%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Bluechiip Ltd (ASX: BCT)
    Latest News

    A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
    Technology Shares

    Bluechiip (ASX:BCT) share price explodes 63% on Fujifilm deal

    The company is planning for a big 24 months ahead...

    Read more »

    BCT ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Bluechiip Ltd

    Bluechiip Ltd is engaged in the development and commercialization of a wireless tracking solution. It serves healthcare and life science, security, defence, and manufacturing industries. Its product includes Retrofit Button For CryoVials; CryoVial Box; CryoTag; Matchbox Reader; Multi-Vial Reader; Hand-Held Reader; Stream Sample-Management Software; Blood Cassettes; and Towers/Racks/Frames.

    BCT Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    04 Dec 2023 $0.02 $0.00 0.00% 685,069 $0.02 $0.02 $0.02
    01 Dec 2023 $0.02 $0.00 0.00% 246,700 $0.02 $0.02 $0.02
    30 Nov 2023 $0.02 $0.00 0.00% 727,479 $0.02 $0.02 $0.02
    29 Nov 2023 $0.02 $0.00 0.00% 860,401 $0.02 $0.02 $0.02
    27 Nov 2023 $0.02 $0.00 0.00% 96,600 $0.02 $0.02 $0.02
    24 Nov 2023 $0.02 $0.00 0.00% 213,947 $0.02 $0.02 $0.02
    23 Nov 2023 $0.02 $0.00 0.00% 380,952 $0.02 $0.02 $0.02
    21 Nov 2023 $0.02 $0.00 0.00% 116,927 $0.02 $0.02 $0.02
    16 Nov 2023 $0.02 $0.00 0.00% 773,400 $0.02 $0.02 $0.02
    15 Nov 2023 $0.02 $0.00 0.00% 530,000 $0.02 $0.02 $0.02
    13 Nov 2023 $0.02 $-0.01 -40.00% 1,319,552 $0.03 $0.03 $0.02
    09 Nov 2023 $0.03 $0.00 0.00% 613,881 $0.02 $0.03 $0.02
    07 Nov 2023 $0.02 $0.00 0.00% 1,181,099 $0.02 $0.02 $0.02

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    01 Nov 2023 Andrew McLellan Expiry 3,133,333 $62,666
    As advised by the company. 4,766,667 Performance Rights, lapsed
    30 Jun 2023 Andrew McLellan Issued 4,900,000 $102,900
    Issue of securities. 7,900,000 Performance Rights, As per announcement on 06-07-2023
    29 Jun 2023 Andrew McLellan Issued 750,000 $15,750
    Conversion of securities.
    29 Jun 2023 Andrew McLellan Exercise 750,000 $15,750
    Conversion of securities. 13,49,602 Rights
    30 May 2023 Michael Ohanessian Issued 800,000 $20,000
    Participation in share purchase plan.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Iain MacGregor Crawford Kirkwood Non-Executive DirectorNon-Executive Chairman Nov 2007
    Mr Kirkwood is a private consultant, investor and non-executive Director. He has practical and operational experience gained from a financial career spanning 35 years in a range of industries including auditing, resources, manufacturing and latterly healthcare in Australia, Britain and the USA. He started his career at Arthur Andersen & Co in London. During his career, he has held a range of senior financial and general management positions, including Woodside Petroleum Limited, Santos Limited, Pilkington plc, F.H. Faulding & Co Limited and Clinuvel Pharmaceuticals Limited.
    Mr Michael B. Ohanessian Non-Executive Director Dec 2014
    Mr Ohanessian has executive experience gained from technology-related businesses with a mixture of operational, strategic and leadership capabilities. Following a ten-year career at Mobil Oil, Michael joined the Boston Consulting Group where he consulted to clients in a range of industries which include banking, airlines, mining, packaging, sports, oil and gas, retailing and biotechnology. Michael later moved on to be the CEO of Vision BioSystems, a division of the former publicly listed Vision Systems Limited, where he transformed the business over seven years from a small unprofitable contract manufacturer into a vertically integrated, profitable and growing medical diagnostics business with distribution to over 60 countries. He has also served as Chief Executive of Genetic Technologies Limited and has been involved in investment management and corporate advice with Lion Capital.
    Mr Andrew McLellan Chief Executive OfficerManaging Director Jan 2015
    Mr McLellan has experience in innovation and commercialisation combined with technical and operational experience. Prior to joining Bluechiip, he was the CEO of Advanced Manufacturing Co-operative Research Centre (AMCRC) which he now serves as a non- executive Director. Andrew focused on bringing together industry and research to develop and commercialise ground-breaking innovations. He has held a range of senior positions including Director at Leica Microsystems Pty Ltd, Vice President of Marketing and Business Development North America and Director of Product Management at Vision BioSystems Pty Ltd.
    Mr Andrew Cox Non-Executive Director Jul 2017
    Mr Cox has experience in emerging and international markets. Andrew was a co-founder and former chairman of private equity-funded media/ technology business Inlink (sold to ASX-listed oOh! Media Ltd in 2015, and is a co-founder of iPro Pty Ltd. Andrew began his career with KPMG in Melbourne before moving to China and Hong Kong, where he spent seven years with SG Warburg, the Australian Trade Commission and Ernst & Young. He is a member of the Translation and Commercialisation Committee of the Murdoch Children's Research Institute and is fluent in Mandarin Chinese.
    Ms Chelsea Sheridan Company Secretary Jan 2022
    Chelsea Sheridan Company Secretary

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hsbc Custody Nominees (Australia) Limited 100,834,755 14.13%
    Bnp Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> 31,943,930 4.48%
    J P Morgan Nominees Australia Pty Limited 29,027,271 4.07%
    Mutual Trust Pty Ltd 18,381,336 2.58%
    Dr Stephen Frederick Woodford 18,200,000 2.55%
    Mr Iain Macgregor Crawford Kirkwood 15,774,949 2.21%
    Allhc Pty Ltd <Sam Hupert Family A/C> 13,040,000 1.83%
    Bramscorp Pty Ltd <Gilbert Family S/Fund A/C> 8,783,102 1.23%
    Edward St Consulting Pty Ltd <Kirkwood Family S/Fund A/C> 8,320,037 1.17%
    Talento Holdings Pty Ltd 7,866,667 1.10%
    Citicorp Nominees Pty Limited 7,179,441 1.01%
    Richard Seville And Associates Pty Ltd <The Seville Super Fund A/C> 6,961,567 0.98%
    Hsbc Custody Nominees (Australia) Limited - A/C 2Mr Michael Bernard Ohanessian 6,959,737 0.98%
    Spurgin Smsf Pty Ltd <Spurgin Smsf A/C> 6,750,000 0.95%
    Alltogether Pty Ltd <Alltogether Super Fund A/C> 6,001,322 0.84%
    Brendan Luxton Investments Pty Ltd 6,000,000 0.84%
    Corpdan Investments Pty Limited <Mcguirk Super Fund A/C> 5,709,468 0.80%
    Ansata Investments Pty Ltd <Ansata Investment A/C> 5,674,087 0.80%
    Belladonna Holdings Pty Ltd <Belladonna Super Fund A/C> 5,460,601 0.77%
    Adam James Winstanley & Mrs Jody Annette Winstanley <Winsland Superannuation A/C> 5,065,032 0.70%